Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

Cetuximab 6Cisplatin 4zalutumumab 3Radiotherapy 3Docetaxel 3Fluorouracil 2Carboplatin 2temsirolimus 1pembrolizumab 1osimertinib 1enzalutamide 1cobimetinib 1abemaciclib 1Taxes 1Sorafenib 1Risk Factors 1Radiation 1Papanicolaou Test 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Imatinib Mesylate 1Human Papillomavirus DNA Tests 1Gefitinib 1Everolimus 1Erlotinib Hydrochloride 1Cyclophosphamide 1Colposcopy 1Cilengitide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Squamous Cell × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡